A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas.
Latest Information Update: 10 Feb 2020
At a glance
- Drugs Bevacizumab (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 28 Jan 2020 Status changed from active, no longer recruiting to completed.
- 11 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019.
- 16 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov record.